Essential Access Health
UEI KNVJQY9UH316 · CA · SAM.gov record ↗
$-9K
FY2025 obligations
3
Contract awards
Jul 15, 2013
First action
Jul 31, 2025
Latest action
Obligations by agency
- Department Of Health And Human Services$-9K
Obligations by NAICS
Monthly obligations
Oct 24
Nov 24
Mar 25
Aug 25
Contracts ending within 18 months (recompete watch)
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75N94020F00001 ↗ | CORE FUNCTION ACTIVITIES | National Institutes Of Health | 541714 | $-3K | Jul 31, 2020 | Jul 30, 2026 |
Largest awards
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75N94023F00001 ↗ | NICHD: R&D: OVAPRENE PHASE 1: PROTOCOL FINALIZATION, REGULATORY APPROVAL, START-UP, AND COMMENCEMENT OF RECRUITMENT, SCREENING, AND ENROLLMENT FOR THE OVAPRENE VAGINAL DEVICE CLINICAL TRIAL | National Institutes Of Health | 541714 | $0 | Sep 27, 2023 | May 29, 2025 |
| 75N94020F00001 ↗ | CORE FUNCTION ACTIVITIES | National Institutes Of Health | 541714 | $-3K | Jul 31, 2020 | Jul 30, 2026 |
| HHSN27500002 ↗ | A MULTI-CENTER, RANDOMIZED STUDY TO EVALUATE THE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE, CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL LOW DOSE ULIPRISTAL ACETATE | National Institutes Of Health | 541712 | $-6K | Jul 15, 2013 | Mar 30, 2022 |